Editorial Article

Dr. A.R. Shabaraya

M.Pharm.Ph.D., MBA, MD (AM)

Editor, RJPS

Principal & Director,

Srinivas College of Pharmacy, Valachil, Mangalore - 574 143

E-mail: cell: 9448428200

Year: 2018, Volume: 8, Issue: 1, Page no. 4-5,
Views: 472, Downloads: 6
Licensing Information:
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0.


  • 1

Dear Readers,

In the year 2018, I foresee Pharmacy profession likely to face many challenges. The main challenge would be to face the onslaught of imports of pharmaceuticals from China. The changes that may occur in the pharmaceutical industry may reflect on job market potential which has direct bearing on Pharmacy education system. So it has almost become mandatory to incorporate necessary changes in the curriculum also in tune with the changes in the Pharma Industry.

Of course, it is easier said than done, the frequent changes in the curriculum, its implementation may not have smooth ride. It is saddled with administrative and executive bottle necks.

Off late, there is a bolt from the blue i.e e-Pharmacy issue. The rapid utilisation of latest technology many result in many benefits and also associated implications. The Govt of India has sought the opinion of state Govts regarding the rules to be drafted pertaining to

e-Pharmacies. The rules (Drugs and cosmetics 1945, drugs and cosmetics amendment rules 2017) require little modification to the existing drug laws. The sale of drugs through

e-pharmacies would curtail the profit margins of community pharmacies along with the job prospects of associated work force as they feel. A lot of heat has already been generated in the media and on many professional platforms about the concept of e-pharmacies. The profession is yet to see the outcome of their implementation and their effect on marketing sector.

Another issue is, drugs technical advisory broad (DTAB) has given a report regarding the FDC (Fixed dose combinations) as per the directions of the Supreme Court. One expert committee opined the FDC s dosing pattern is not in line with potency of ingredients, hence their therapeutic efficacy and toxicity. This would certainly affect the Pharma companies who are mainly involved in the manufacture of FDCS, ultimately this may / may not impact the job potential.

Some of the issues that are highlighted in this editorial, require rational thinking, can also be classified under contemporary issues require to be debated, investigated at the academic level for logical outcomes.

RGUHS journal of Pharm sciences has been striving hard to bring out articles contributed by Pharma research fraternity. It is the endeavour of the editorial team to maintain the standards of the journal on sustainable basis.

Supporting Files
No Pictures


We use and utilize cookies and other similar technologies necessary to understand, optimize, and improve visitor's experience in our site. By continuing to use our site you agree to our Cookies, Privacy and Terms of Use Policies.